[Activated prothrombin complex preparations for the treatment of anticoagulant hemophilia. Preparation--method of operation--supply possibility].
The mechanism of the bypass activity of prothrombin complex preparatives for treatment of haemophiliacs with circulating anticoagulants remains unclear up to now. The following parameters had been tested with preparatives produced in a different manner (absorption by DEAE-Sephadex A 50, Molselekt A 50, tricalcium phosphate or aluminium hydroxide): Coagulation factors II, VII, IX, X and XII, activated factors VIIa and Xa as well as the FEIB activity. The bypass activity is strongly correlated to the factor VIIa content of the preparatives, however. These results agree with the statements by HEDNER and KISIEL, which had used a factor VII a concentrate for treatment of haemophilia complicated by circulating anticoagulants with success. According to farther investigations factor VII is correlated with the lipid content of the starting plasma. This knowledge is important for optimizing the production procedure of prothrombin complex preparatives with bypassing activity.
Wilms
K
K
Bezirksinstitut für Blutspende- und Transfusionswesen Rostock.
Sander
W
W
D000042:Absorption; D000925:Anticoagulants / Q000097:blood*; D001779:Blood Coagulation Factors / Q000032:analysis / Q000302:isolation & purification / Q000502:physiology / Q000627:therapeutic use*; D002852:Chromatography, Ion Exchange; D005167:Factor VII / Q000627:therapeutic use; D006467:Hemophilia A / Q000097:blood / Q000628:therapy*; D006801:Humans
D000925:Anticoagulants; D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D005167:Factor VII
Aktivierte Prothrombinkomplexpräparate (PK) zur Behandlung der Hemmkörperhämophilie. Herstellung--Wirkungsweise--Einsatzmöglichkeit.